Zimbabwe has turned down a significant American health deal valued at $367m (£272m) spanning five years over the United States' insistence on confidential biological samples.
This rejection came to light following a government memo from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the deal was "unbalanced".
A government spokesman has since explained that the US was requesting genetic material for research and profit but refused to share the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for further dialogue to find a deal suitable to all parties so the nation's critical HIV programme can continue.
Broader Implications
This rejection follows a comparable case in neighbouring Kenya, where a court blocked a similar health funding agreement after legal challenges were raised about the safety of citizens' health data.
After resuming office last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the US government, but Trump claimed its spending was "inefficient" and his government was seeking government-to-government agreements to enhance transparency and accountability.
According to statements, Sixteen African countries have so far signed these new health pacts, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million presently on HIV treatment via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, without any corresponding guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"Effectively, our country would supply the basic resources for scientific discovery with no certainty that the resulting innovations would be accessible to our population should a future pandemic arise."
National Interest and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures previously set up via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to manage future pandemics.
"This system is intended to guarantee that when a nation provides its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to develop them."
These objections regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome further discussions with our American counterparts on how future collaboration might be structured in a manner that respects the independence and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but urged that talks must proceed given that much of the country's HIV programmes relied on international support.
"In cases where specific concerns arise, including those involving information security or implementation frameworks, these can often be resolved via technical clarification and negotiated safeguards," the group added.
The halted deal highlights the ongoing tensions between receiving vital foreign assistance and safeguarding local interests in an ever more data-driven world.